Addison Capital Co Purchases 4,569 Shares of iShares Biotechnology ETF $IBB

Addison Capital Co lifted its holdings in iShares Biotechnology ETF (NASDAQ:IBB) by 16.0% during the 1st quarter, Holdings Channel.com reports. The firm owned 33,045 shares of the financial services provider’s stock after buying an additional 4,569 shares during the period. iShares Biotechnology ETF makes up about 1.0% of Addison Capital Co’s investment portfolio, making the stock its 26th largest position. Addison Capital Co’s holdings in iShares Biotechnology ETF were worth $5,580,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in IBB. Basepoint Wealth LLC bought a new stake in shares of iShares Biotechnology ETF during the 4th quarter valued at $26,000. Cary Street Partners Financial LLC bought a new position in iShares Biotechnology ETF in the 4th quarter worth $29,000. Darwin Wealth Management LLC bought a new position in iShares Biotechnology ETF in the 2nd quarter worth $25,000. Caitlin John LLC purchased a new position in iShares Biotechnology ETF during the fourth quarter valued at $34,000. Finally, Cornerstone Planning Group LLC purchased a new position in iShares Biotechnology ETF during the fourth quarter valued at $35,000. Hedge funds and other institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Price Performance

NASDAQ:IBB opened at $198.23 on Wednesday. The stock has a 50-day simple moving average of $174.23 and a two-hundred day simple moving average of $172.27. iShares Biotechnology ETF has a 52-week low of $128.06 and a 52-week high of $198.71.

iShares Biotechnology ETF Cuts Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, June 18th. Investors of record on Monday, June 15th were paid a dividend of $0.0238 per share. The ex-dividend date was Monday, June 15th. This represents a $0.10 dividend on an annualized basis and a dividend yield of 0.0%.

About iShares Biotechnology ETF

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.